Mucosal Vaccine Design and Delivery

被引:159
作者
Woodrow, Kim A. [1 ]
Bennett, Kaila M. [2 ,3 ]
Lo, David D. [2 ]
机构
[1] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA
[2] Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA
[3] Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA
来源
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 14 | 2012年 / 14卷
关键词
mucosal immunity; mucosal adjuvant; particulate delivery; biomaterial vaccine vectors; VIRUS-LIKE PARTICLES; HEAT-LABILE ENTEROTOXINS; HUMAN CERVICAL-MUCUS; TOLL-LIKE RECEPTORS; EPITHELIAL M-CELLS; CD8(+) T-CELLS; DENDRITIC CELLS; IMMUNE-RESPONSES; DRUG-DELIVERY; IN-VIVO;
D O I
10.1146/annurev-bioeng-071811-150054
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Mucosal surfaces are a major portal of entry for many human pathogens that are the cause of infectious diseases worldwide. Vaccines capable of eliciting mucosal immune responses can fortify defenses at mucosal front lines and protect against infection. However, most licensed vaccines are administered parenterally and fail to elicit protective mucosal immunity. Immunization by mucosal routes may be more effective at inducing protective immunity against mucosal pathogens at their sites of entry. Recent advances in our understanding of mucosal immunity and identification of correlates of protective immunity against specific mucosal pathogens have renewed interest in the development of mucosal vaccines. Efforts have focused on efficient delivery of vaccine antigens to mucosal sites that facilitate uptake by local antigen-presenting cells to generate protective mucosal immune responses. Discovery of safe and effective mucosal adjuvants are also being sought to enhance the magnitude and quality of the protective immune response.
引用
收藏
页码:17 / 46
页数:30
相关论文
共 178 条
[1]   The protective role of antibody responses during Mycobacterium tuberculosis infection [J].
Abebe, F. ;
Bjune, G. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 157 (02) :235-243
[2]   Vaccine adjuvants revisited [J].
Aguilar, J. C. ;
Rodriguez, E. G. .
VACCINE, 2007, 25 (19) :3752-3762
[3]   HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide [J].
Alfsen, A ;
Bomsel, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (28) :25649-25659
[4]   Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery [J].
Alpar, HO ;
Somavarapu, S ;
Atuah, KN ;
Bramwell, V .
ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (03) :411-430
[5]   LIPOSOMES AS CARRIERS OF ANTIGENS AND ADJUVANTS [J].
ALVING, CR .
JOURNAL OF IMMUNOLOGICAL METHODS, 1991, 140 (01) :1-13
[6]   EFFECT OF CHITOSAN ON THE PERMEABILITY OF MONOLAYERS OF INTESTINAL EPITHELIAL-CELLS (CACO-2) [J].
ARTURSSON, P ;
LINDMARK, T ;
DAVIS, SS ;
ILLUM, L .
PHARMACEUTICAL RESEARCH, 1994, 11 (09) :1358-1361
[7]   Mucosal HIV vaccines: A holy grail or a dud? [J].
Azizi, Ali ;
Ghunaim, Haitham ;
Diaz-Mitoma, Francisco ;
Mestecky, Jiri .
VACCINE, 2010, 28 (24) :4015-4026
[8]   Nasal mucosal administration of chitin microparticles boosts innate immunity against influenza A virus in the local pulmonary tissue [J].
Baaten, B. J. G. ;
Clarke, B. ;
Strong, P. ;
Hou, S. .
VACCINE, 2010, 28 (25) :4130-4137
[9]   Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns [J].
Bachmann, Martin F. ;
Jennings, Gary T. .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (11) :787-796
[10]  
Bagwe RP, 2001, CRIT REV THER DRUG, V18, P77